Beckman Coulter Life Sciences, a subsidiary of Danaher Corporation, has announced the launch of the Cydem VT Automated Clone Screening System, an innovative platform designed to transform the world of drug discovery through advanced laboratory automation and innovation. This groundbreaking technology aims to streamline the process of selecting top clones in biologic drug discovery and monoclonal antibody-based therapeutics, with a particular focus on the Cell Line Development (CLD) process. This new system promises to significantly improve efficiency and reliability in laboratory workflows.
Key Features and Benefits
Reduction in Manual Labor
The Cydem VT System boasts a remarkable capability to reduce the labor-intensive manual steps involved in Cell Line Development by up to 90% within a single experiment. This reduction in manual labor not only minimizes reliance on traditional screening steps but also significantly streamlines the overall workflow. As a result, researchers can focus their efforts on more critical tasks that require their expertise. Automation plays a crucial role in making the entire process faster and more efficient, leading to quicker results and higher productivity.
In addition, the system’s automation capabilities ensure consistency and accuracy in the screening process, reducing the risk of human error and enhancing the reliability of the outcomes. By automating repetitive and mundane tasks, the Cydem VT System frees up valuable time for researchers to concentrate on high-value activities, such as data analysis and interpretation. This shift enables laboratories to operate more efficiently, accelerating the pace of drug discovery and ultimately improving the chances of developing successful therapeutics.
High-Throughput Platform
The Cydem VT System leverages high-throughput microbioreactor technology to facilitate automated top clone screening. This advanced technology allows for the simultaneous analysis and cultivation of multiple samples, which is essential for enhancing productivity and reducing the time-to-market for new therapeutics. By handling numerous samples at once, researchers can quickly identify the most promising clones, thereby accelerating the overall drug discovery process.
The high-throughput capabilities of the system enable researchers to screen a large number of clones in a shorter period, increasing the likelihood of finding high-quality candidates. Furthermore, the ability to analyze and cultivate multiple samples simultaneously ensures that researchers can efficiently manage their workload and make informed decisions based on a comprehensive dataset. This acceleration of the screening process is particularly beneficial in the competitive field of biologic drug discovery.
Improved Reliability and Cultivation Conditions
Early insights into cell growth and productivity stages are crucial for reliable clone selection, and the Cydem VT System excels in this regard by providing these early answers. This early information results in more dependable clones that are less likely to fail in later stages of development. The system’s ability to maintain cultivation conditions that closely mimic biomanufacturing production levels further enhances the accuracy of screening results. By ensuring that the selected clones perform well in large-scale production, the system reduces the risk of costly failures down the line.
Consistent and optimal cultivation conditions are essential for generating reliable and reproducible results in clone screening. The Cydem VT System’s advanced monitoring and control capabilities ensure that all parameters are kept within the desired range, creating an environment conducive to cell growth and productivity. This meticulous control over cultivation conditions translates into higher-quality data and more reliable clone selection, ultimately improving the efficiency and success rate of the Cell Line Development process.
Automated Operations
Walk-away Time
One of the standout features of the Cydem VT System is its automated operations, which offer an impressive walk-away time of at least three days during experimentation. This feature allows laboratory personnel to focus on other critical tasks without needing to constantly monitor the system. The ability to leave the system unattended for extended periods without compromising the quality of the results is a significant advantage for busy research facilities. It not only enhances overall lab efficiency but also optimizes resource allocation.
The extended walk-away time provided by the Cydem VT System is a game-changer for research laboratories, enabling scientists to allocate their time and resources more effectively. By automating routine and time-consuming tasks, the system allows researchers to concentrate on more complex and innovative aspects of their work. This increased flexibility and efficiency translate into higher productivity and faster progress in drug discovery projects.
Continuous Monitoring
The Cydem VT System includes non-invasive online measurements of pH, dissolved oxygen (DO), and biomass, enabling continuous and precise control over cultivation parameters. This continuous monitoring helps maintain optimal conditions throughout the screening process, ensuring that the cells are always in the best possible environment for growth and productivity. The ability to monitor these parameters in real-time provides researchers with valuable data that can be used to make informed decisions about the selection of top clones.
Real-time monitoring of critical parameters is essential for maintaining the health and productivity of cell cultures. The Cydem VT System’s advanced monitoring capabilities allow researchers to track changes in cultivation conditions and make adjustments as needed to ensure optimal performance. This level of control and precision is invaluable in the Cell Line Development process, as it enables researchers to identify and select the best-performing clones with greater confidence and accuracy.
On-deck Determination
The Cydem VT System also features on-deck facilities for determining cell concentration, viability, and titer concentration. This integrated approach ensures that all necessary measurements are taken on-site, providing researchers with immediate feedback on the performance of their clones. The ability to make these determinations quickly and accurately is crucial for the efficient selection of the best-performing clones, further streamlining the Cell Line Development process and enhancing overall productivity.
Having on-deck determination capabilities within the same system eliminates the need for additional equipment and reduces the time required to obtain essential data. This streamlined workflow allows researchers to make prompt and informed decisions about the selection and optimization of clones. The integration of these measurement capabilities within the Cydem VT System exemplifies Beckman Coulter Life Sciences’ commitment to providing comprehensive and efficient solutions for the scientific community.
Impact on Drug Discovery and Therapeutics
Addressing Common Challenges
The introduction of the Cydem VT System addresses common challenges in biologic drug discovery and therapeutic development, such as the selection of low-productivity clones. By providing early and accurate results, the system helps researchers quickly identify viable candidates with high accuracy. This improvement is particularly impactful in research areas focusing on autoimmune diseases and various types of cancer, where the need for effective therapeutics is critical.
The ability to identify high-quality clones early in the development process significantly reduces the risk of costly failures and accelerates the overall path to market. By addressing these common challenges, the Cydem VT System enhances the efficiency and success rate of biologic drug discovery projects, ultimately leading to the development of more effective therapies for patients.
Enhancing Research Efficiency
Dr. Sebastian Hofzumahaus, the Product Manager, emphasized the system’s role in expediting critical research therapies. By reducing the risk of selecting non-productive clones and providing early and accurate results, the Cydem VT System ensures that laboratories can achieve breakthroughs faster. This acceleration in the research process ultimately enhances human health outcomes. New therapies can be developed and brought to market more quickly, benefiting patients who rely on innovative treatments for improved quality of life.
The Cydem VT System’s advanced capabilities streamline the research workflow and enable laboratories to operate with greater efficiency and precision. By minimizing the time and resources required for clone screening, the system allows researchers to focus on the development and optimization of new therapies. This increased efficiency not only accelerates the discovery process but also enhances the overall quality and effectiveness of the resulting treatments.
Related Developments
History of Innovation
Beckman Coulter Life Sciences has a long history of innovation in laboratory automation, continually advancing the field with groundbreaking products. Previous product launches, such as the QbD1200+ Total Organic Carbon Analyzer, the Biomek NGeniuS Next Generation Library Prep System, and the CytoFLEX nano Flow Cytometer, underscore the company’s commitment to advancing laboratory processes and improving research efficiency. These products have set the stage for the introduction of the Cydem VT System, demonstrating the company’s ongoing dedication to providing cutting-edge solutions for the scientific community.
The Cydem VT System builds on this legacy of innovation, incorporating advanced technologies and features that address the needs of modern research laboratories. Beckman Coulter Life Sciences’ commitment to pushing the boundaries of what is possible in laboratory automation is evident in the continuous development and refinement of their product offerings.
Commitment to Advancing Laboratory Processes
The company’s continuous efforts to enhance laboratory workflows and improve research outcomes are evident in its latest offering, the Cydem VT System. This new system is a testament to Beckman Coulter Life Sciences’ commitment to innovation and excellence. By integrating advanced technologies and providing comprehensive features, the system represents a significant step forward in the field of biologic drug discovery and therapeutic development.
The Cydem VT System embodies the company’s mission to empower researchers with the tools they need to achieve their goals efficiently and accurately. Beckman Coulter Life Sciences’ dedication to improving laboratory processes and providing high-quality solutions has made them a trusted partner in the scientific community. Their ongoing commitment to innovation continues to drive advancements in research and healthcare.
Company Background
Beckman Coulter Life Sciences
Founded in 1935, Beckman Coulter Life Sciences has established itself as a leader in laboratory automation and innovation. The company’s dedication to empowering scientists by providing solutions that enhance speed, accuracy, and advanced analytics in laboratory workflows has been a driving force behind their success. As a subsidiary of Danaher Corporation, Beckman Coulter Life Sciences operates globally with headquarters in Indianapolis, Indiana, and employs approximately 2,800 associates. With over 400,000 systems installed worldwide, the company continues to be a trusted partner in fields such as Centrifugation, Flow Cytometry, Genomics, Particle Analysis, and Liquid Handling.
Beckman Coulter Life Sciences’ extensive experience and expertise in laboratory automation have enabled them to develop a diverse range of products that address the needs of researchers across various disciplines. Their commitment to innovation and excellence is reflected in the quality and performance of their solutions, making them a reliable and respected name in the scientific community.
Conclusion
Beckman Coulter Life Sciences, a branch of the Danaher Corporation, has unveiled the Cydem VT Automated Clone Screening System, a cutting-edge technology poised to revolutionize drug discovery. This innovative platform is specifically designed to enhance laboratory automation and innovation in the field, offering a streamlined approach to selecting the most promising clones in biologic drug discovery and monoclonal antibody-based therapeutics. With a special emphasis on the Cell Line Development (CLD) process, the Cydem VT system is set to significantly boost efficiency and reliability in laboratory workflows. This launch represents a massive leap forward in the efficiency and precision of drug discovery methods, promising to transform the entire landscape by automating complex tasks and reducing the risk of human error. Consequently, researchers can now focus more on innovative development rather than tedious manual processes, ultimately accelerating the pace of bringing new, effective therapies to market.
